Предыстория и актуальность
New trials and approvals of targeted and immune-oncologic therapies have enriched the options for first-line systemic therapy of advanced and metastatic ccRCC.
This language version is in progress; translations will be added gradually.
New trials and approvals of targeted and immune-oncologic therapies have enriched the options for first-line systemic therapy of advanced and metastatic ccRCC.